Brandberg, Yvonne http://orcid.org/0000-0001-9840-9266
,
Johansson, Hemming
Hellström, Mats
Gnant, Michael
Möbus, Volker
Greil, Richard
Foukakis, Theodoros
Bergh, Jonas
Funding for this research was provided by:
Cancerfonden (180842)
Article History
Received: 30 September 2019
Accepted: 18 March 2020
First Online: 31 March 2020
Compliance with ethical standards
:
: Six of the authors declare that they have no conflict of interest. Professor Volker Möbus declare remuneration from Klinikum Frankfurt Höcht and advisory roles for Amgen, Roche and Tesaro. Professor Richard Greil declare remuneration from MSD, Abbvie and Sandos, advisory roles for Celgene, Roche, Takeda, Merck, Astra Zeneca, Novarits, BMS, Daischi and Sitead, Abbvie and Jansen. He has also been funded by Celgene, Merck, Takeda, Astra Zeneca, Novarits, Amgen, BMS, Sandoz and Roche.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Swedish part of the randomized Panther study received ethical approval by the Karolinska Institutet Regional Ethical Board, Dnr 2007/4–32, January 24, 2007.
: The physician including the patient in the study introduced the HRQOL evaluation orally and in written. Consenting patients received the baseline questionnaire together with an envelope. After completion, the questionnaire put in the envelope was collected by the physician. The reason for using an envelope at this assessment point was to prevent that the treating physicians had access to the completed questionnaires. This procedure enabled the patient to respond more freely, minimizing bias due to social desirability. At subsequent HRQOL assessments, the patients were handed the questionnaires and envelopes by the research nurses. Completed questionnaires were considered as informed consent in the HRQoL study.